Back to Search

Amgen Inc

AMGN

Biotechnology • Biotechnology

$417.20
+6.25 (+1.52%)

Market Cap: $222.2B

Price Chart

4/10

criteria met

Verdict

Overvalued

Amgen Inc (AMGN) meets 4 of 10 fundamental criteria on Stoxly's checklist. The fundamentals may be sound, but the current valuation looks stretched. The P/E or PEG ratio suggests the price has outpaced financial performance.

For educational purposes only — not financial advice. Data may be delayed.

Valuation

Is the stock reasonably priced for what you get?

P/E Ratio

25.4
Target: < 25 Not met

PEG Ratio

5.5
Target: < 2.0 Not met

Price/Book Ratio

20.4
Target: < 3.0 Not met

EV/EBITDA

N/A
Target: < 15Data not available

Growth & Profitability

How fast is the business growing and how efficiently does it earn money?

Revenue Growth

11.8%
Target: > 10% Criteria met

ROE

89.1%
Target: > 5% Criteria met

Operating Margin

25.4%
Target: > 10% Criteria met

Return on Assets

8.5%
Target: > 5% Criteria met

Financial Health

Can the company comfortably cover its obligations?

Quick Ratio

0.8
Target: > 1.5 Not met

Debt/Equity Ratio

6.3
Target: < 1.0 Not met

Free Cash Flow Yield

N/A
Target: > 0%Data not available

Dividend Yield

2.45%
Informational

Dig deeper before you buy

The research platforms we reach for when a stock passes the first screen:

Some links above are affiliate links — Stoxly may earn a commission if you open an account or subscribe, at no extra cost to you. This never influences analysis results. Affiliate disclosure